Our Pricing

Mounjaro in Andover: Access, Pricing, and Clinical Guidance

Published: 3 October 2026

Residents searching for Mounjaro Andover now have access to this clinically proven weight loss treatment through Cured Pharmacy, a UK-registered online service offering tirzepatide injections from £124.99 with free prescriber consultations and discreet delivery across Hampshire. Our GPhC-registered team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), provides comprehensive clinical assessments to determine suitability for Mounjaro, ensuring safe and legal access for eligible patients in the Andover area. All treatments require approval from a UK-registered prescriber following an online consultation that typically takes under three minutes.

How to Access Mounjaro Andover Through Cured Pharmacy

Obtaining Mounjaro Andover is straightforward through our regulated online service. Patients complete a confidential medical questionnaire covering weight history, current medications, cardiovascular health, and contraindications such as medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2[1]. Our UK-registered prescribers review each assessment individually, typically within hours, and approve treatment only when clinically appropriate.

Once approved, Mounjaro is dispensed from our GPhC-registered pharmacy (9012511) and delivered discreetly to your Andover address via next-day courier in plain, unmarked packaging. The service includes ongoing prescriber support, dosage titration guidance, and access to our clinical team throughout your treatment journey. New patients receive £20 off their first order using code Weightlossnew, reducing the starting price to £124.99.

Mounjaro Andover Pricing and Dosage Options

Mounjaro Andover is available from £124.99 per four-week supply at Cured Pharmacy, with pricing varying by dosage strength. The treatment follows a structured dose-escalation protocol: patients begin with 2.5mg weekly for four weeks, then increase to 5mg weekly[2]. Further titration to 7.5mg, 10mg, 12.5mg, or the maximum 15mg occurs at four-week intervals based on tolerability and weight loss response.

This graduated approach minimises gastrointestinal side effects while optimising efficacy. In the SURMOUNT-1 trial, participants achieved average weight reductions of 15-20.9% over 72 weeks depending on final dose, with the 15mg strength delivering the greatest results[2]. Our transparent pricing model shows costs upfront before consultation, ensuring no hidden fees for Andover patients.

Dose Escalation Schedule for Mounjaro Andover Patients

The standard titration schedule spans 20 weeks to reach the maintenance dose: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), 12.5mg (weeks 17-20), and finally 15mg for ongoing treatment[1]. Prescribers may adjust this timeline if patients experience persistent nausea, vomiting, or diarrhoea, allowing additional time at lower doses before advancing. This individualised approach ensures Mounjaro Andover patients achieve optimal outcomes while maintaining tolerability.

Clinical Evidence Supporting Mounjaro Andover Use

Mounjaro Andover prescribing is underpinned by robust clinical trial data from the SURMOUNT programme. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, randomising them to tirzepatide (5mg, 10mg, or 15mg) or placebo[2]. At 72 weeks, participants on the 15mg dose lost an average of 20.9% body weight compared to 3.1% with placebo, representing a clinically significant difference.

Beyond weight reduction, Mounjaro demonstrated improvements in cardiometabolic markers: HbA1c decreased by up to 0.5% in non-diabetic participants, systolic blood pressure fell by an average of 7.4mmHg, and triglyceride levels improved significantly[3]. These benefits make Mounjaro Andover particularly valuable for patients with metabolic syndrome, prediabetes, or cardiovascular risk factors. The MHRA licensed tirzepatide for chronic weight management in adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity[1].

Mounjaro Andover Safety Profile and Contraindications

The most common side effects reported in Mounjaro Andover patients mirror those in clinical trials: nausea (affecting 20-30% of users), diarrhoea, vomiting, constipation, and reduced appetite[2]. These gastrointestinal symptoms typically diminish after several weeks as the body adapts. Serious adverse events are rare but include pancreatitis, gallbladder disease, and hypoglycaemia when combined with insulin or sulfonylureas.

Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous severe hypersensitivity to tirzepatide[1]. Prescribers carefully screen for these conditions during the online assessment, ensuring safe prescribing for Andover residents.

Mounjaro Andover vs Other Weight Loss Treatments

Patients in Andover often compare Mounjaro to alternative weight loss medications such as Wegovy (semaglutide) and Saxenda (liraglutide). Head-to-head trials suggest tirzepatide produces greater weight loss than semaglutide: the SURPASS-2 study found tirzepatide 15mg led to 11.2kg average weight reduction versus 5.7kg with semaglutide 1mg in type 2 diabetes patients[4]. While no direct comparison exists in obesity-only populations, the SURMOUNT and STEP trial results suggest Mounjaro may offer superior efficacy.

Mounjaro Andover patients benefit from once-weekly subcutaneous injections using the pre-filled KwikPen device, identical in convenience to Wegovy and Saxenda. However, Mounjaro's dual GIP/GLP-1 receptor agonism provides a unique mechanism that may enhance satiety and metabolic effects beyond GLP-1 agonism alone[3]. Our comparison table below details key differences in type, frequency, and pricing to help Andover residents make informed decisions subject to prescriber approval.

Who Can Access Mounjaro Andover Prescriptions

Mounjaro Andover is licensed for adults aged 18 and over with a body mass index of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease[1]. Patients must also demonstrate commitment to lifestyle modification, including reduced-calorie diet and increased physical activity, as Mounjaro is intended as an adjunct to behavioural changes rather than a standalone solution.

Certain populations require additional caution or are ineligible for Mounjaro Andover treatment. Pregnant or breastfeeding women cannot use tirzepatide due to insufficient safety data. Patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or active gallbladder disease require specialist evaluation before initiation[1]. Our prescribers assess each Andover patient individually, ensuring treatment aligns with MHRA guidance and clinical best practice.

Mounjaro Andover Lifestyle Integration

Successful Mounjaro Andover outcomes depend on integrating the medication with sustainable lifestyle changes. Clinical trials required participants to follow a reduced-calorie diet (typically 500kcal deficit) and engage in at least 150 minutes of moderate-intensity physical activity weekly[2]. Our clinical team provides guidance on nutrition, exercise, and behavioural strategies to maximise weight loss and maintain results after treatment completion. Patients who combine Mounjaro with structured lifestyle programmes achieve the most durable outcomes.

Starting Mounjaro Andover Treatment Today

Beginning Mounjaro Andover is simple through Cured Pharmacy's streamlined online service. Navigate to our medical consultation page, complete the brief questionnaire covering medical history and weight management goals, and submit for prescriber review. Most assessments receive a decision within hours during business days. If approved, your first Mounjaro prescription is dispensed immediately and dispatched for next-day delivery to your Andover address in discreet packaging.

New patients benefit from £20 off using code Weightlossnew, reducing the initial cost to £124.99. Ongoing prescriptions are managed through your secure patient account, with automatic reminders before each four-week supply is due. Our superintendent pharmacist Tarun Kumar and the wider clinical team remain available via phone (+44 116 4646009) for questions about injection technique, side effect management, or dose adjustments throughout your Mounjaro Andover journey[5].

Mounjaro Andover Delivery and Packaging

All Mounjaro Andover orders are shipped in plain, unbranded packaging with no external indication of contents, ensuring complete privacy. Medications are packaged with temperature-controlled materials to maintain the required 2-8°C storage during transit. Upon arrival, store your Mounjaro KwikPens in the refrigerator immediately and do not freeze. Each pen contains four weekly doses; rotate injection sites between abdomen, thigh, and upper arm to minimise injection-site reactions[1]. Detailed administration instructions and sharps disposal guidance are included with every order.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. EMC. [accessed 3 October 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 3 October 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 3 October 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 3 October 2026]
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity. NICE Technology Appraisal Guidance. [accessed 3 October 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 3 October 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 3 October 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 3 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.